1156170-01-2Relevant academic research and scientific papers
BROMODOMAIN INHIBITORS
-
Paragraph 1207, (2014/06/24)
The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
METHYLPYRROLOPYRIMIDINECARBOXAMIDES
-
Page/Page column 105, (2012/06/18)
The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.
METHYLPYRROLOPYRIMIDINECARBOXAMIDES
-
Page/Page column 168, (2011/04/14)
The compounds of formula (I) wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, and the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiestera
METHYLPYRROLOPYRIDINECARBOXAMIDES
-
Page/Page column 86, (2011/04/14)
The compounds of formula (I) wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, and the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase.
